Debt pressures cast cloud over Fosun Pharma results
The drugmaker eked out a 0.16% rise in first-half revenue, but underlying net profit slipped 26% as waning sales of Covid treatments and foreign exchange losses squeezed earnings Key Takeaways:…
2196.HK
600196.SHG
Recent Articles
Debt pressures cast cloud over Fosun Pharma results
2196.HK
600196.SHG
RELATED ARTICLES
-
Fosun moves on from debt crisis with renewed focus on tourism, healthcare
0656.HK
-
Fosun Tourism travels back to home base with delisting plan
1992.HK 0656.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
-
BRIEF: Fosun pledges 27% of Fosun Pharma’s A-shares
2196.HK 600196.SHG
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
Hengrui Pharma accelerates bid for global brand status
600276.SHG
Discover hidden China stock gems in our weekly newsletter